Novartis NVS announced that the EMA accepted its application for migraine candidate AMG Novartis released data from its RTH clinical trials illustrating that RTH does not need to be injected as often as Regeneron's rival drug, Eylea. Markets close nvs stock options 2 hrs 52 mins.

Today's Charts Nike gains on Amazon talk; Citi downgrades Target; Oracle earnings on tap. People also watch GSK SNY AZN LLY ABT. Summary Conversations Statistics Profile Financials Options Holders Historical Data Nvs stock options.

Data Disclaimer Help Suggestions. Privacy About Our Ads Terms Updated.

It's offensive Something else Thank you for helping us improve your Yahoo experience It's not relevant It's distracting I don't like this ad Send Done Why do I see ads? Learn more about your feedback.